Delivering better treatments
Camurus is committed to improving the lives of patients
with severe and chronic diseases
updates
Latest news
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2024/2027
Camurus to present at Jefferies 2024 Healthcare Conference New York
Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly
Disease areas
Focus on severe and chronic diseases
Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care
Events
Upcoming events
-
03 Jun
BIO International Convention 2024
Camurus will participate in this conference in San Diego, CA, US, 3-6 June, 2024.
-
05 Jun
Jefferies New York Healthcare Conference
Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in New York on 5 June at 1pm ET. Webcast
-
16 Jul
Interim Report January-June 2024
The interim report January-June is published on 16 July 2024.
Latest financial report
Camurus’ Interim Report January-March 2024
8 May 2024
Annual General Meeting
Camurus’ Annual General Meeting 2024 was held on Wednesday, 8 May 2024 at Elite Hotel Ideon in Lund, Sweden.
See documents for Annual General Meeting 2024
See resolutions at the Annual General Meeting 2024
See more information on Camurus' general meetings
Pipeline
Diversified pipeline with large potential
Camurus' innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
sustainability
Sustainable solutions for a healthier world
Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.